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Background: To find out the prevalence of active hepatitis C virus (HCV) infections among general public in Lahore
city, since data concerning the prevalence of active HCV in this city is currently unavailable.
Methods: Blood samples were collected randomly from individuals visiting different clinical laboratories in Lahore.
Serum was separated and processed by nested PCR qualitative assay for the detection of HCV RNA. The samples
were categorized into different age groups on the basis of pre-test questionnaires in order to record the age-wise
differences regarding the prevalence of active HCV. Data were analyzed statistically using Chi-Square test.
Results: Out of the 4246 blood samples analyzed in this study, 210 were confirmed to be positive for active HCV
infection. Gender-wise active HCV prevalence revealed no significant difference [OR = 1.10 CI = (0.83-1.46), p > 0.05].
However, among the age groups the highest prevalence was observed in the age groups 20–29 (7.7%) and 30–39 years
(6.4%) with odds of prevalence of 14.8% (OR = 2.48, CI = (1.40-4.38), p < 0.05) and 10.3% (OR = 2.03, CI = (1.10-3.71),
respectively. In age groups above 40 years (40–49, 50–59 and >59 years), a decrease in levels of active HCV prevalence
was observed.
Conclusions: Among tested samples, 4.9% of the subjects were confirmed to harbour active HCV infections and the
“middle aged” population in Lahore was found to be at a higher risk of the HCV ailments compared to both their
younger and older peers.
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Hepatitis C is an infectious liver disease of humans and
chimpanzees and is caused by the HCV [1]. The infec-
tion is often asymptomatic especially in its early stages
but once established, it can progress to advanced liver
diseases such as liver fibrosis and ultimately cirrhosis.
These liver diseases can further lead to other complica-
tions such as liver failure and liver cancer [2]. In 2004,
the World Health Organization (WHO) reported that
annual deaths all over the world due to liver cancer and
cirrhosis caused by HCV were about 308,000 and
785,000, respectively [3]; and about 200 million people,
the 3.3% of the world’s population, are infected with
HCV [4]. Moreover, around 3 to 4 million individuals
are diagnosed as new cases every year [5].* Correspondence: hamzamgondal@gmail.com
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reproduction in any medium, provided the orIn Pakistan an alarming rate of HCV outbreaks have
been reported. The previous estimates indicate that
around 10 million people are infected with HCV in
Pakistan [6-8]. Prevalence of HCV has been noticed to
be highly variable in different regions and even in differ-
ent groups of the same community [9]. According to
various studies, the presence of HCV infections among
different categories (excluding chronic liver disease pa-
tients), was 5.31% in Islamabad [10], 0.4-31.9% in various
regions of Punjab province [6,7,11-13], 4-6% in Sindh
province [6,7,13,14], 1.1-9% in Khyber Pakhtunkhwa
province [6,7,13,15-17], 1.5% in Quetta region [12,13]
and 25.7% in Gilgit Baltistan province [18,19]. While in
Lahore, the second largest city of Pakistan with a popu-
lation of more than 7 million [20], HCV prevalence was
estimated from 0.58-17.78% [6,13,19,21-24].
Two major issues undermine the credibility of the
published data: firstly, the number of samples included
in most of the cohort studies were too small; secondly,Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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made it highly inappropriate to conduct a formal meta-
analysis to assess the accurate national prevalence [7].
Most of the studies conducted so far, have relied on the
presence of anti-HCV antibodies in the blood samples
using immunochromatographic tests (ICT), enzyme im-
munoassay (EIA), recombinant strip immunosorbent
assay (RIBA) and enzyme linked immunosorbent assay
(ELISA) techniques. All these techniques are fairly error
prone and have been reported to generate around 50%
false positive results as compared to PCR confirmatory
assay [15]. Approximately 60-85% of HCV patients can
develop chronic hepatitis, while the remaining 15-40%
can clear the HCV infection. A number of these individ-
uals, however, can still be detected as HCV positive
using non-PCR immunoassays such as ELISA, RIBA,
EIA, ICT etc., due to the presence of anti-HCV anti-
bodies in their blood [15]. Nevertheless, to date there is
hardly any PCR based prevalence studies conducted in
Pakistan with statistically representative number of sam-
ples. PCR has emerged as the most powerful diagnostic
tool for the detection, quantification and genotyping of
active HCV RNA in the blood.
In the present study, over 4000 blood samples were
randomly collected from individuals visiting different
clinical laboratories in Lahore, Pakistan. These samples
were screened through confirmatory nested PCR qualita-
tive assay to determine the percent prevalence of active
HCV in various subjects. To the best of our knowledge,
this is the first comprehensive report concerning the
prevalence of active HCV in Pakistan’s 2nd largest city
and its surroundings, with a statistically significant num-
ber of samples. The data was also correlated and catego-
rized in terms of gender and age groups. This report will
thus provide the HCV prevalence data for further meta-
analysis that can help to devise strategies by the health
policy makers for the control of hepatitis C disease.
Results
Out of 4246 blood samples, 1914 were collected from
male and 2332 from female subjects. Moreover, all the in-
dividual samples were categorized into six age groups.
The PCR results revealed that 210 (4.9%) individuals had
active HCV infection (Table 1). Gender-wise prevalence of
active HCV infection was estimated to be 5.27% in male
(101 positive out of 1914 samples) and 4.67% in female
subjects (109 positive out of 2332 samples), respectively.
Although the probability trends were slightly higher
among males of all age groups than females, statistically
there was no significant difference in gender with OR =
1.10 CI = (0.83-1.46), p >0.05, as elaborated in Table 1.
Substantial differences were observed considering the
age group criterion. Out of the 458 individuals tested in
ages ranging from 9–19 years (both male and female),only 15 (3.3%) were HCV positive. The highest numbers
of positive individuals (69) with 7.7% prevalence were
among the tested subjects (891) in the age group 20–
29 years (Table 1 and Figure 1). Statistically, the odd of
prevalence of HCV in individuals in age group 20–
29 years was 14.8% higher than the individuals in age
group 9–19 years (OR = 2.48,CI = (1.40-4.38), p < 0.05),
as illustrated in Table 1.
In the age group 30–39 years, HCV prevalence,
though slightly less than that found for the 20–29 year
group, was still significantly higher (10.3%) as compared
to age group 09–19 years (OR = 2.03, CI = (1.10-3.71).
Subsequently, a decreasing trend of HCV prevalence
was observed with increasing age of subjects above
40 years. The lowest prevalence (3%) of active HCV was
observed in the age group 59 years and above. Overall
active HCV prevalence among all the tested samples was
estimated to be 4.9% and the risk of HCV prevalence
was significantly higher in the middle age groups (20–29
& 30–39 years).
Discussion
In Pakistan, ~6% population is suspected to be infected
with HCV [6,7,25] and HCV prevalence data published
so far is highly variable. In most of the studies con-
ducted so far, either the number of samples reported
are too small to draw any solid conclusion or the meth-
odological differences have made it impossible to conduct
a formal meta-analysis to determine accurate prevalence
estimates [7]. Among all the published reports, 99% of
the data originated from erroneous non-PCR qualitative
screening methodologies, mostly based on the detection
of anti-HCV antibodies. Active HCV prevalence esti-
mated during our research (4.9%) is lower than that re-
ported by Aslam et al. [24] (6.7% based on 488 samples
from the general population of Lahore). Similarly, the
current estimate is much lower when compared with a
nationwide data surveillance study conducted through
an ELISA blood screen by Qureshi, et al. [12], who re-
ported 6.8% HCV prevalence in Lahore based general
public. Our estimates were, however, much higher than
those of another study in which 203 blood samples from
staff and students of University of the Punjab, Lahore,
were assayed through ELISA by Tanvir et al. in 2008
[26]. In yet another series of research conducted in
pediatric population by Khan et al. [22], Parker et al.
[23] and Hyder et al. [27] HCV prevalence was reported
as 4.09%, 1.3% and 0.58%, respectively, which is again
lower as in comparison to our reported results (Table 2).
The only PCR-based HCV active prevalence study con-
ducted in Lahore was reported by Zafar et al. [28] for a co-
hort of pregnant women. Out of 300 screened samples,
4% were found to be positive. Although this figure is rela-
tively close to our figure (4.9%) the number of samples













9-19 458 9/211 6/232 0.0343 0.0313 – – 3.3
20-29 891 31/399 38/423 0.0810 0.0741 0.002 2.48 7.7
(1.40-4.38)
30-39 625 24/258 16/327 0.0672 0.0614 0.023 2.03 6.7
(1.10-3.71)
40-49 654 14/296 19/325 0.0529 0.0483 0.155 1.57 5.1
(0.84-2.93)
50-59 730 11/298 15/406 0.0375 0.0342 0.779 1.10 3.6
(0.57-2.09)
> 59 888 12/351 15/510 0.0321 0.0292 0.831 0.93 3.0
(0.49-1.77)
Total 4246 101/1813 109/2223 0.0508b 0.0464b – – 4.9
aRepresents the estimated probabilities of HCV prevalence in male and female in different age groups calculated using the inverse transformation of logistic
regression model. bAverage probability of six age groups of both genders. cThe goodness of fit tests Pearson, deviance, and Hosmer-Lemeshow for the model
have p values ranging from 0.312 to 0.724 indicating the logistic regression model fit adequately HCV prevalence data. dCI (Confidence Interval) for male gender
was 1.10 (0.83-1.46) with p value 0.497.
Distribution of positive & negative in gender as well as age groups based criteria.
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our active HCV prevalence estimate in general public of
Lahore city is much lower than the values reported by
Chaudhary et al. [29] and Akhtar et al. [21] among blood
donors in Lahore, which revealed HCV prevalence as
6.06% and 17.78%, respectively; indicating highly variable
results (Table 2). Both studies were conducted using
ELISA as a screening tool. HCV prevalence in IDUs [30]
and haemophilia patients [31], reported as 88% and 56%
respectively, are much higher in comparison with our
results.
Gender-wise HCV prevalence revealed no significant



















Figure 1 Prevalence of HCV positive samples in male/female populatand female populations, as detailed in Table 1. Our study
is in agreement with the previous country-wide as well
as Lahore based surveys [12,20,32]. It is, however, in
contrast with a recent study showing female to male
ratio of 1:16.5 (Table 2) presumably due to the subjects
were restricted only to blood donors and ELISA was
used as a diagnostic tool [21].
Considering the age group criterion, significant differ-
ences were observed in the prevalence of HCV in both
genders. The highest prevalence 7.7% and 6.4% were
observed in age groups 20–29 and 30–39 years, respect-
ively; with odds of prevalence of 14.8% (OR = 2.48, CI =
(1.40-4.38), p < 0.05) and 10.3% (OR = 2.03, CI = (1.10-0-59 > 59 Total
Positive Male
Positive Female
ion in different age groups.
Table 2 Previous HCV prevalence data among different communities of Lahore
Ref. # Population type Author Methods Population size HCV (%)
[24] General population Aslam et al. 2001 ICT 488 6.70
[26] General population Tanvir et al. 2008 ICT 203 1.48
[12] General population Qureshi et al. 2010 ELISA –a 6.80
[11] General population Bosan et al. 2010 ICT, Lattix 1501b 2.1-13.5
[22] Pediatric population Khan et al. 1996 EIA, RIBA 538 4.09
[23] Pediatric population Parker et al. 1999 ELISA 538 1.30
[27] Pediatric population Hyder et al. 2001 ELISA 171 0.58
[28] Pregnant women Zafar et al. 2001 PCR 300 4.00
[11] Bosan et al. 2010 ELISA 4108b 6.8-7.3
[29] Blood donors Chaudhary et al. 2005 ELISA 890 6.06
[11] Blood donors Bosan et al. 2010 EIA, ELISA, ICT 32326b 4.1-6
[21] Blood donors Akhtar et al. 2013 ELISA 245 17.78
[31] Hemophilia Malik et al. 2006 ELISA 100 56
[11] Other high risk groups Bosan et al. 2010 ELISA 412b 19-56
aIn this national survey, samples collected from Lahore region were not mentioned.
bData from a number of locally published reports, reviewed by Bosan et al. 2010 [11], have been combined.
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pared to the age group 9–19 years. In age groups above
40 years (40–49, 50–59 and >59 years), a decreasing
trend of active HCV prevalence was observed (Table 1).
These results are in agreement with the previous studies
particularly those conducted in Lahore city revealing the
higher risk of HCV prevalence in middle aged groups
(20–40 years) [20,24,33,34]. The high prevalence of
HCV in middle aged groups can be correlated to more
exposure of HCV infection and other risk factors such
as non-blood transfusions, widespread reuse of syringes,
and a range of other high-risk traditional practices.
Conclusions
Using the PCR based diagnostic assay for 4246 blood
samples, the overall prevalence of active HCV was esti-
mated as 4.9% in general public of Lahore. No signifi-
cant differences in male and female genders were
observed. However, HCV prevalence varied in different
age groups. It was least prevalent in age groups 9–19
and above 59 years. However, middle aged populations,
especially 20–29 and 30–39 year individuals were ob-
served at higher risk of hepatitis C ailments with 7.7%
and 6.4% active HCV prevalence, respectively. This re-
port will provide the active HCV prevalence data for
further meta-analysis, which can be helpful to health
policy makers to devise strategies for the control of
hepatitis C disease in Lahore in particular and in Pakistan
in general. From the results of the present study, future
PCR-based studies will result in lowering the previously
reported estimates (i.e. 6%) of prevalence of HCV in
Pakistan.Methodology
Collection of blood samples
In this study, 4246 blood samples were collected ran-
domly from individuals visiting different clinical labora-
tories of Lahore between 2010 and 2012. As the study
was designed to represent the general public HCV
prevalence, the samples were collected randomly from
individuals who visited laboratories for any purpose such
as some clinical test, sample submission, report collec-
tion or blood screen etc. Samples were collected from
both genders having ages ranging from 9 to > 59 years.
Informed consent was taken from every individual being
tested and approval was obtained from institutional eth-
ical review committee. History of individuals was re-
corded in the form of questionnaires. Serum from each of
these blood samples were separated by centrifugation at
4000 rpm for 5 min. Each sample was properly labeled
and stored at −20°C until (on every coming Monday) it
was shifted to National Institute for Biotechnology &
Genetic Engineering (NIBGE) Faisalabad for PCR diag-
nostic assay. Besides the gender groups, samples were also
categorized into six age groups to determine the preva-
lence in each age group.
Viral RNA extraction and cDNA formation
RNA was extracted from these samples using the Qiamp
Viral RNA extraction kit (Qiagen, USA) according to
manufacturer’s instruction. Serum sample (140 μl) was
used to extract RNA that was eluted in 60 μl elution
buffer supplied with kit. RNA was used in making cDNA
immediately after extracting RNA or stored at −80°C for
further use. cDNA was prepared in a total reaction
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each sample. For cDNA formation, First Strand cDNA syn-
thesis kit (Thermo scientific, USA) was used. Briefly, the ex-
tracted RNA was mixed with 20 picomol of gene specific
primer (5′ GTGCACGGTCTACGAGACCT 3′) and 200
units Moloney Murine Leukemia Virus (M-MuLV) reverse
transcriptase and incubated at 42°C for 60 min with light
shaking. After incubation, cDNA was properly labeled and
stored at −20°C for PCR amplification.
Polymerase chain reaction amplification of cDNA
Amplification of cDNA was performed according to
Petrelli [35]. A reaction mixture of 50 μl containing
5 μl of cDNA, 0.2 mM dNTPs, 2 mM MgCl2, 0.5 μM
of forward primer, 0.5 μM of reverse primer, 2.5 U of
Taq DNA Polymerase and 1X Taq polymerase Buffer
(75 mM Tris–HCl pH 8.8, 20 mM (NH4)2SO4, 0.01%
Tween) [Fermentas] was prepared and amplification was
carried out in a thermal cycler (Biorad). For amplification
of first round of PCR, conditions used were 94°C for
2 min followed by 30 cycles with the temperature profile
94°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec and
final extension was performed for 2 min at 72°C. The PCR
products were used as template for nested PCR ampli-
fication. The temperature conditions were the same
as in the first round of PCR except the primers used,
which were complementary to the PCR product of
first round PCR [36].
Analysis of PCR product
The amplified PCR products of nested PCR were run
on 1% agarose gel prepared in 1X TBE (Trizma base,
boric acid) buffer. Ethidium bromide dye (3 μL,
1% w/v) was also added in order to make the bands
visible under UV light. The samples were loaded into
the well by mixing with bromophenol blue and gel
was run under constant voltage of 80 until the dye
reached the other end of the gel. The bands were vi-
sualized under UV light. The sensitivity of the PCR
based qualitative assay was noticed around 200 IU per ml
of the sample.
Statistical analysis
All of the PCR based HCV qualitative data were sta-
tistically analyzed using Minitab version 16.2 for Win-
dows. Binary Logistic regression was performed in
order to examine the prevalence of HCV associated
with sex and age. Statistical tests of the regression es-
timates or odds ratios (OR) were based on Wald sta-
tistics. The Hosmer-Lemeshow statistics has suggested
that the logistic regression model fit the data ad-
equately and 95% confidence intervals for odd ratios
were calculated. A p-value < 0.05 was defined as sta-
tistically significant.Abbreviations
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ICT: Immunochromatographic; EIA: Enzyme immunoassay; RIBA: Recombinant
strip immunosorbent assay; ELISA: Enzyme linked immunosorbent assay;
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DNA; WHO: World Health Organization; OR: Odd ratio; CI: Confidence interval.
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